TITLE

The Barcelona Brief

AUTHOR(S)
LOONEY, WILLIAM
PUB. DATE
October 2016
SOURCE
Pharmaceutical Executive;Oct2016, Vol. 36 Issue 10, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article presents a document entitled "Prospects, Analysis and Trends in Global Pharma 2016" prepared by a chief executive officer (CEO) panel of experts for the annual CPhI trade show organized by UBM, the parent company of "Pharmaceutical Executive" magazine taking place in Barcelona, Spain in October 2016. Topics discussed include generic geographies, quality culture and innovative sprint for biologics. The key role of technology in streamlining manufacturing costs is also explored.
ACCESSION #
120515866

 

Related Articles

  • The process validation paradigm shift. Doyle, B. G. // Caribbean Business;7/15/2010, Vol. 38 Issue 27, p42 

    The article features the paradigm shift of the process validation. It states that validation is a quality system which is a crucial part of the industry's Regulatory Compliance program. Elizabeth Plaza, chief executive officer and president of global operations at PharmaBioServ Inc., shares her...

  • Changing places. Plagakis, Jim // Drug Topics;5/17/99, Vol. 143 Issue 9, p46 

    Presents views on the role of chief executive officers (CEO) in a pharmaceutical company. Importance of pharmacists; Concern of a CEO.

  • Who's who in pharmaceutical industry.  // Economic Review (05318955);Aug96, Vol. 27 Issue 8, p33 

    Profiles three prominent chief executives of pharmaceutical companies in Pakistan. Brookes Pharmaceutical Labs president A. Haseeb Khan; Glaxo Wellcome Pakistan managing director Nighat Parveen; Highnoon Laboratories Ltd. chief executive Jawaid Tariq Khan.

  • Excipient Pedigree as a Supply Chain Tool. Falk, Arthur J. // Pharmaceutical Technology;Mar2010, Vol. 34 Issue 3, p78 

    The article focuses on excipients as a supply chain tool in the pharmaceutical industry. It notes that companies spend much time, effort and money to ensure excipient quality to prevent life-threatening changes to the excipient as it makes its way through the supply chain. It states that the...

  • BioLife banks on preservation methods to drive sales. Tampone, Kevin // Business Journal (Central New York);10/7/2005, Vol. 19 Issue 40, p31 

    The article profiles BioLife Solutions Inc., a company which develops technologies focused on preserving live biological materials through freezing and cooling. John Baust, president and CEO, says that a variety of research organizations have a need for preserved biological materials. Most of...

  • DOCTORS' ORDERS. Michels, A.J. // Fortune;6/15/1992, Vol. 125 Issue 12, p13 

    Describes various health practices among chief executive officers (CEO) that head pharmaceutical companies. Options for exercise; Dietary considerations; Comments from Amgen CEO Gordon Binder; Theodore Cooper of Upjohn; John Stafford of American Home Products.

  • REGIONAL REPORT: TRIANGLE.  // Business North Carolina;Nov2004, Vol. 24 Issue 11, p12 

    Presents news briefs on business and industries in the triangle region of North Carolina as of November 2004. Key reason for the replacement of bioMerieux CEO Philippe Sans with Eric Bouvet; Recruitment of Charles Peters Jr. at Red Hat; Decision of the state Division of Facility Services to the...

  • Start anywhere, ask questions and fail early. Arnold, Matthew // Medical Marketing & Media;May2010, Vol. 45 Issue 5, p28 

    The article presents the insights of chief executive officers (CEOs) on the future of the pharmaceutical industry in the U.S.

  • Former Geneva head to lead B2B health exchange.  // Drug Store News;8/14/2000, Vol. 22 Issue 11, p6 

    Announces that David Hurley has been named chief executive officer of a business-to-business health exchange formed by four drug distributors in the United States. Responsibilities of Hurley; Information on the company.

  • The Management Behind the Molecules. Van Arnum, Patricia // Chemical Market Reporter;3/17/2003, Vol. 263 Issue 11, pFR11 

    Focuses on key revenue drivers outlined by chief executive officers in pharmaceutical industry. Financial performance in 2002; Projected transition in 2003 in terms of new drug development and product launches; Key therapeutic areas.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics